Adherence Intervention for Breast Cancer Treatment Compliance
Trial Summary
What is the purpose of this trial?
To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, since the study focuses on adherence to both endocrine therapy and cardiovascular medications, it seems likely that you will continue taking them.
What data supports the effectiveness of the Multicomponent Adherence Intervention treatment for breast cancer treatment compliance?
Research shows that multicomponent interventions, which involve active patient participation, are effective in improving adherence to treatments. Additionally, good communication between patients and healthcare providers significantly boosts adherence to hormone therapies in breast cancer patients.12345
Is the Adherence Intervention for Breast Cancer Treatment Compliance safe for humans?
How is the Multicomponent Adherence Intervention treatment different from other treatments for breast cancer?
The Multicomponent Adherence Intervention is unique because it focuses on improving patients' adherence to their prescribed breast cancer treatments, which is often a challenge. It likely includes strategies like patient education, better communication with healthcare providers, and possibly technology-based tools to support patients in sticking to their treatment plans.58111213
Research Team
Dawn Hershman, MD
Principal Investigator
Columbia University
Eligibility Criteria
The IMPACT Trial is for men and women over 18 with early-stage breast cancer who are on endocrine therapy and a CVD medication but have trouble sticking to their treatment. They must be within 3 years of completing initial treatments like surgery or chemo, speak English or Spanish, and see a doctor in the New York Presbyterian Health system.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a multicomponent adherence intervention for endocrine therapy and CVD medication
Follow-up
Participants are monitored for adherence and health outcomes after the initial treatment phase
Treatment Details
Interventions
- Multicomponent Adherence Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Columbia University
Lead Sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborator